About RevBio
RevBio is a company based in Lowell (United States) founded in 2014 by Michael Brown, Brian Hess, Jonathan Slotkin, George Kay, and Grayson Allen. RevBio has raised $24.42 million across 16 funding rounds from investors including NIH, Pacific Dental Services and HHS. RevBio offers products and services including TETRANITE. RevBio operates in a competitive market with competitors including SINTX, MiMedx Group, Ossio, Theradaptive and EpiBone, among others.
- Headquarter Lowell, United States
- Founders Michael Brown, Brian Hess, Jonathan Slotkin, George Kay, Grayson Allen
-
Sectors
HealthcareChemicals & Materials
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Revbio Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$24.42 M (USD)
in 16 rounds
-
Latest Funding Round
$1.7 M (USD), Grant
Sep 01, 2024
-
Investors
NIH
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of RevBio
RevBio offers a comprehensive portfolio of products and services, including TETRANITE.
Synthetic adhesive for bone repair and fixation in medical procedures.
People of RevBio
Unlock access to complete
Unlock access to complete
Funding Insights of RevBio
RevBio has successfully raised a total of $24.42M across 16 strategic funding rounds. The most recent funding activity was a Grant round of $1.7 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in RevBio
RevBio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Pacific Dental Services and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage entrepreneurs are accelerated through MassChallenge's program.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for RevBio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by RevBio
Investment portfolio details for RevBio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - RevBio
Detailed financials for RevBio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Revbio Comparisons
Peer comparison for RevBio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RevBio
RevBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SINTX, MiMedx Group, Ossio, Theradaptive and EpiBone, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Silicon nitride medical devices are manufactured for interbody fusion.
|
|
| Locked | Locked | Locked |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics
|
|
| Locked | Locked | Locked |
Orthopedic fixation is enabled by bone regeneration biocomposite technology.
|
|
| Locked | Locked | Locked |
Therapeutic delivery platform is developed for orthopedic clinical indications.
|
|
| Locked | Locked | Locked |
Developer of stem cells to regrow damaged bones
|
|
| Locked | Locked | Locked |
Synthetic calcium composites are developed for bone repair and regeneration.
|
Detailed competitors of RevBio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Revbio
Complete news archive for RevBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RevBio
RevBio was founded in 2014 and raised its 1st funding round 1 year after it was founded.
RevBio is headquartered in Lowell, United States. It is registered at Lowell, Massachusetts, United States.
Brian Hess is the current CEO of RevBio. They have also founded this company.
RevBio is a funded company, having raised a total of $24.42M across 16 funding rounds to date.
RevBio was founded in 2014 in Lowell, United States, within the biotechnology sector. Synthetic adhesives for bone and dental repair are developed using proprietary Tetranite technology, a bio-engineered protein derived from worms. Applications include implant stabilization, fracture repair, spine fusion, dental bone grafting, joint reconstruction, and cranial flap fixation, with operations centered on advancing these medical solutions.
RevBio's top competitors include EpiBone, Theradaptive and MiMedx Group.
RevBio offers TETRANITE.
RevBio has 5 investors. Key investors include NIH, Pacific Dental Services, HHS, University of Pittsburgh, and MassChallenge.